Kishor G. Bhatia - 19 Sep 2025 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
Chief Scientific Officer
Signature
/s/ Kishor G. Bhatia
Issuer symbol
LTRN
Transactions as of
19 Sep 2025
Net transactions value
$0
Form type
4
Filing time
23 Sep 2025, 16:05:14 UTC
Previous filing
17 Jul 2024
Next filing
22 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bhatia Kishor G. Chief Scientific Officer 1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS /s/ Kishor G. Bhatia 22 Sep 2025 0001812638

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LTRN Stock Option (Right to Buy) Disposed to Issuer $0 -52,200 -100% $0.000000 0 15 Jun 2020 Common Stock 52,200 $15.00 Direct F1
transaction LTRN Stock Option (Right to Buy) Award $0 +52,200 $0.000000 52,200 15 Jun 2020 Common Stock 52,200 $5.04 Direct F1
transaction LTRN Stock Option (Right to Buy) Disposed to Issuer $0 -17,400 -100% $0.000000 0 29 Oct 2021 Common Stock 17,400 $10.21 Direct F2
transaction LTRN Stock Option (Right to Buy) Award $0 +17,400 $0.000000 17,400 29 Oct 2021 Common Stock 17,400 $5.04 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date).
F2 The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021.